CARB‑X awarded funding to accelerate two point‑of‑care diagnostic efforts: ProtonDx received $1 million to evaluate a blood‑based host RNA assay for pediatric lower respiratory infections using its Lacewing instrument in collaboration with Imperial College London; Scout Health won up to $6 million to finalize a low‑cost, loop‑mediated isothermal amplification system for chlamydia and gonorrhea and to begin pilot studies in low‑ and middle‑income countries. Both grants target assays that could reduce inappropriate antibiotic use and speed correct treatment. The awards reflect persistent funder emphasis on rapid diagnostics to combat antimicrobial resistance and improve pediatric infectious disease management.